Internal Reference Number: FOI_7039
Date Request Received: 21/02/2023 00:00:00
Date Request Replied To: 14/03/2023 00:00:00
This response was sent via: By Email
Request Summary: Incidence and treatment of breast cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab + Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 2 • Abemaciclib + Fulvestrant 3 • Alpelisib + Fulvestrant 1 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab + Nab-paclitaxel/Paclitaxel 2 • Capecitabine as a single agent 9 • Eribulin as a single agent or in combination 2 • Everolimus + Exemestane 1 • Fulvestrant as a single agent 4 • Lapatinib 0 • Neratinib 1 • Parp Inhibitors (Olaparib/Talazoparib) 1 • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 32 • Palbociclib + Fulvestrant 5 • Pembrolizumab 1 • Platinum (e.g. carboplatin or cisplatin) as a single agent 0 • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 2 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan 0 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 8 • Taxane and/or Anthracycline in combination 0 • Trastuzumab as a single agent or in combination 2 • Trastuzumab emtansine 3 • Transtuzumab deruxtecan 1 • Any other active systemic anti-cancer therapy - 0 | |
| Question Number 2: Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with: • early/locally advanced breast cancer (Stages 1 to 3B) • advanced/metastatic breast cancer (Stages 3C and 4) | |
| Answer To Question 2: Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with: • early/locally advanced breast cancer (Stages 1 to 3B) 1 • advanced/metastatic breast cancer (Stages 3C and 4) 2 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
